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Abstract
Background: Porcine cirovirus type 1 (PCV1) and type 2 (PCV2) are circulating in Chinese pig herds and the
infected pigs develop antibodies to both viruses. Current commercial available ELISA kits cannot differentiate PCV2-
specific antibodies from the mixtures of PCV1 and PCV2 antibodies in PCV1/2-infected or PCV2-vaccinated pigs.
Therefore, the need for developing PCV2-specific ELISA methods is urgent to evaluate PCV2 antibody level in
exclusion of PCV1 antibody interference after PCV2 vaccination.
Results: Virus-like particles (VLPs) of PCV2 based on the recombinant Cap protein were expressed in Escherichia coli. A
competing ELISA was established by using the VLPs as coating antigen and a PCV2-specific monoclonal antibody as the
competing antibody. The competing ELISA was compared with the results obtained by using an immunoperoxidase
monolayer assay on 160 serum samples. The sensitivity and specificity of this competing ELISA were determined as 96.5
and 96.0 %, at 2 standard deviation from the mean or 91.8 and 100 % at 3 standard deviations from the mean. Next, a
serological survey of 1297 vaccinated serum samples collected from commercial pig herds in Beijing, Hunan and Henan
provinces in China was conducted. The results showed that 85.9 % of sera having positive PCV2 antibodies.
Conclusions: The competing ELISA we developed in this study was both sensitive and specific to PCV2 and was suitable
for large-scale PCV2 antibody monitoring in exclusion of PCV1 antibody interference after PCV2 vaccination.
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Background
Porcine circovirus (PCV) was first identified as a noncyto-
pathic contaminant of PK-15 cell, and subsequently classi-
fied in the family Circoviridae [1]. PCV is a spherical non-
enveloped virus with a diameter of approximately 17 nm,
and a single-stranded closed circular genomic DNA 1.7 kb
in size [2]. There are two genotypes of PCV, namely PCV1
and PCV2. Serological analysis reveals that cross-reactivity
exists between PCV1 and PCV2 [3]. PCV1 is widely known
to be nonpathogenic agent, and no discernible pathogenic
have been associated with PCV1 infection in swine [4].
Conversely, PCV2 is related to several diseases, such as
postweaning multisystemic wasting syndrome (PMWS),
porcine dermatitis and nephropathy syndrome (PDNS),
porcine respiratory disease complex (PRDC), reproductive
disorders, enteritis, and proliferative and necrotizing
pneumonia (PNP), totally as porcine circovirus disease
(PCVD) [5].
PCV2 genome contains two major open reading frames
(ORFs): ORF1 and ORF2. ORF1 encodes the protein which
involves in viral DNA replication, whereas ORF2 encodes
an approximately 30 kDa immunogenic capsid (Cap) pro-
tein [6]. It was reported that the recombinant Cap protein
could self-assemble to form virus-like particles expressed
either in insect cells or Escherichia coli [6, 7]. The recom-
binant Cap protein reacted strongly with serum from
PCV2-infected or PCV2-vaccinated pigs, which suggested
that it was a good candidate antigen for the development of
diagnostic assays [8, 9].
In order to detect PCV2 antibody in serum, the most
common diagnostic methods include indirect fluorescent
assay (IFA) and immunoperoxidase monolayer assay
(IPMA) [10, 11]. However, these tests are not PCV2-
specific due to the fact of antigenic cross-reactivity between
PCV2 and PCV1. Meanwhile, these techniques are not only
time-consuming and labor-intensive, but also require expe-
rienced technicians to judge the result arbitrarily. Com-
pared with the current available methods, Enzyme-linked
immunosorbent assay (ELISA) can be automated which de-
crease the potential bias and fit for mass detection. Several
ELISA assays have been developed using the PCV2 virons or
recombinant Cap protein expressed in insect cells [12–15].
In present study, a competitive ELISA (cELISA), using
virus-like particles (VLP) of PCV2 rCap protein as the
coating antigen and PCV2-specific monoclonal antibody
(MAb) as the detecting antibody, was established. The
establishment of this cELISA will facilitate to simply de-
tect PCV2-specific antibodies from swine serum samples
without PCV1 antibody interference.
Methods
PCV2 antigen and monoclonal antibody preparation
VLPs formed by recombinant Cap protein were pro-
duced in E.coli BL21 (DE3) strain as previously described
[16] and used as the coating antigen for cELISA. Briefly,
the supernatant of cell lysates containing recombinant
Cap (rCap) protein was precipitated by 60 % saturated
ammonium sulfate and resuspended, followed by anion
ion-exchange chromatographic purification. The purified
recombinant PCV2 Cap proteins have been completely
re-assembled into VLPs in a buffer of 50 mM Tris–HCl
and 500 mM NaCl. 200 μl (0.4 μg/μl) recombinant
PCV2 Cap protein plus equal volume of Freund’s
complete adjuvant was used as an immunogen to inject
each of five female Balb/c mice (purchased from Vital
Rivea Experimental Animal Technology Ltd., Beijing) via
intraperitoneal injection for Mab production. Three
booster immunizations with same dose of antigen plus
Freund’s incomplete adjuvant were conducted at two-
week intervals. Three days after the final booster injec-
tion, the mice were euthanized and spleen cells were
fused with SP2/0 cells using standard procedure [17].
The hybridoma cells were maintained in RPMI1640
medium (Gibco, USA) with 17 % fetal bovine serum
(Hyclone, USA). The supernatant of the hybridoma cells
were harvested and tested for antibodies to PCV2 and
PCV1 by IPMA. The colony of 3H11 MAb reactive to
PCV2 but not to PCV1 tested by IPMA was subcloned
two times and selected for use in the cELISA. The MAbs
were labeled with horseradish peroxidase (HRP) accord-
ing to the conventional methods [18].
Serum samples
Five colostrum-deprived specific-pathogen-free piglets
(Purchased from SPF Swine Breeding and Management
Centre, Beijing) were intranasally inoculated with 105.0
TCID50 infective doses of PCV2 SH strain. Serum sam-
ples were collected 0, 7, 14, 21, 28, 35, and 42 days post-
vaccination (dpi) and separated for serological testing by
IPMA and cELISA. Serum samples collected at 0 dpi
worked as negative controls. One hundred and sixty
clinical serum samples stored at National Research
Center for Veterinary Medicine were tested by IPMA for
cELISA development.
In the retrospective serologic study, a total of 1297
field pig serum samples were collected by Veterinary
Diagnostic Laboratory from Beijing (377 samples),
Hunan (432 samples) and Henan (488 samples) prov-
inces in China. The experiments were carried out under
the consent of animal owners. The serum samples were
tested by the cELISA established in this study.
Immunoperoxidase monolayer assay (IPMA)
IPMA was used to detect the presence of antibodies to
PCV2. Briefly, the confluent monolayer of PKK cells (a
PK-15 deprived cell line) infected with PCV2 SH
(MOI=0.01) or free of PCV, were fixed in 80 % acetone
for 30 min at 4 °C. The plates were stored at −20 °C
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after three times washing with PBS (0.01 mol/L, pH7.2).
The MAb or serum samples were diluted 1:50 with PBS
(0.01 mol/L, pH7.2), and added into the PCV2- and
mock-infected PKK cells, respectively, 50 μl/well, and
then incubated at 37 °C for 40 min. The anti-PCV poly-
clonal antiserum (VMRD, USA) and negative serum
gained from colostrums-deprived piglets were respect-
ively prepared as the positive and negative control. After
three times washing, 50 μl of 1:200 dilution of HRP-
conjugated goat anti-mouse or goat-pig IgG (Sigma,
USA) was added and incubated at 37 °C for 30 min.
After three times washing, 50 μl of the substrates 3-
amino-9-ethylcarbazole was added and incubated for
30 min at room temperature. After three times washing,
the 1:10 dilution hematoxylin was added. Twenty sec-
onds later, the plates were washed with water and exam-
ined under an inverted light microscope.
Development of cELISA
Optimized dilution of PCV2 VLP antigen and horserad-
ish peroxidase-conjugated PCV2-specific MAb were
established by systematic checkerboard titrations. The
polystyrene microliter ELISA plates were coated with
1.6 μg PCV2 VLP in phosphate buffer (0.02 mol/L,
pH7.4) at 4 °C for 16 ~ 24 h. After three times washing,
the plates were blocked with 200 μl of 20 % calf bovine
serum in phosphate buffer (0.02 mol/L, pH7.4) for 2 h at
37 °C. After three times washing, 50 μl of the serum
samples were added to each well, then 50 μl of 1:2000
dilution MAb 3H11 conjugated with HRP (Sigma, USA)
were added to the wells except the blank well. The plates
were incubated at 37 °C for 30 min. After five times
washing, 100 μl of the substrate solution (0.2 mg/ml of
TMB and 0.2 % H2O2 in 0.05 mol/L citrate buffer,
pH4.6) was added and the colorimetric reaction was de-
veloped at 37 °C for 15 min. The reaction was stopped
by adding 50 μl of 2 mol/L sulphuric acid. The optical
density (OD) was measured at 450 nm. The controls in-
cluded positive control (in triplicate), negative control
(in triple) and one blank control. The OD450 of the sam-
ples were converted to a percent inhibition (PI) value
using the following formulation: PI (%) = (OD450 value of
negative value −OD450 value of sample)/OD450 value of
negative value × 100 %.
Reproducibility, thermal stability and specificity of the
cELISA
Inter-assay and intra-assay repeatability for the estab-
lished cELISA was evaluated by testing the sixty filed
sera. For the inter-assay repeatability, three replicates of
each serum samples were detected by the same batch of
pre-coated ELISA plates. For the intra-assay repeatabil-
ity, each serum samples were detected by three batches
of pre-coated ELISA plates. Mean PI value and
coefficient of variation (CV) of three replications of each
test were calculated.
Thermal stability for the established cELISA was eval-
uated by testing five filed serums using the plates stored
at 4 and 37 °C for six days, respectively. The PI value of
each serum detected with the plates stored at 37 °C for
six days was compared with those had been stored at 4 °
C. Statistical analysis of the PI value was carried out by
Student’s test using the SPSS 19.0 software. The signifi-
cance level was set at 0.05 (p < 0.05).
To explore the specificity, positive sera for PCV1,
classical swine fever virus (CSFV), high pathogenic
porcine reproductive and respiratory syndrome virus
(HP-PRRSV), porcine parvovirus (PPV), and porcine
pseudorabies virus (PRV) were tested with the estab-
lished cELISA.
Results
Sera from experimentally infected piglets
Standard PCV2-negative and positive serum samples
were house-made by infecting pig with PCV2. Sera from
these pigs sampled at 28, 35 and 42 day post-infection
(dpi) were reactive with PCV2-infected cells by IPMA
and were used as PCV2-postive serum samples. Sera at
0, 7, and 14 dpi were not reactive with PCV2 and were
used as negative serum samples in this study. The posi-
tive sera had OD450 values < 0.719 when tested by
cELISA established in this study with the inhibition in
excess of 77.8 %. By contrast, the negative sera had
OD450 values larger than 1.270 with inhibition less than
60.8 %.
Determination of the cut-off of cELISA by using clinical
sera
A total of 160 field serum samples tested by IPMA were
used to determine the cut-off value of established cELISA
(Table 1). Among them, 75 samples were confirmed to be
serological PCV2-negative by IPMA. These serum sam-
ples were tested by the established cELISA in this study.
Distributions of the cELISA PI values showing the fre-
quency of IPMA-positive and -negative samples are
shown in Fig. 1. The average PI values (x-axis) of the 75
IPMA negative sera detected by cELISA were 34.4 % ±
12.0 % (mean ± SD). When 58.4 % (mean + 2SD) was used
as the cutoff value for percentage inhibition, the sensitivity
was 96.5 % and specificity was 96.0 %, giving a 95 % confi-
dence. When the cutoff increased to 70.4 % (mean + 3SD),
the sensitivity and specificity of the cELISA was 91.8 and
100 %, giving a 99 % confidence.
Reproducibility, thermal stability and specificity of the
cELISA
The reproducibility of the cELISA was determined by
calculating the coefficient of variation (CV) of the PI
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values from field serum samples. The inter-assay CV
of the 40 PCV2-positive serum samples ranged from
0.06 to 4.62 %, while the intra-assay CV of those
same samples ranged from 0.16 to 7.46 % (Table 2).
The inter-assay and intra-assay of the 20 negative
samples also exhibited good repeatability, showing
2.2–14.8 % and 5.1–14.6 % respectively. These data
showed that this assay was repeatable with low and
acceptable variations.
The thermal stability assay was performed by com-
paring the PI values of 5 PCV2 positive serum sam-
ples on different ELISA plates which have been stored
at 4 and 37 °C for six days. The results showed there
was no significant difference (p = 0.107) existed be-
tween these two temperature conditions.
In addition, the cross-reactivity of the cELISA with
several positive sera against CSFV, HP-PRRSV, PPV,
PRV and PCV1 was also tested according to the
cELISA procedures. The OD450 values of all these
sera were in excess of 1.930 (PI ≤ 38.5 %) and were
negative.
Serological survey of PCV2-vaccinated pigs using the
established cELISA
The results for the 1297 field serum samples, collected
from three provinces in China are shown in Table 3. Of
these, 1106 samples were positive (85.3 %) and 191 sam-
ples (14.7 %) were negative for PCV2 antibodies. Region-
ally, the positive rate was 80.6 % (348/432) in Hunan
province, 79.3 % (387/488) in Henan province and
98.4 % (371/377) in Beijing city.
Discussion
PCV2 is currently circulating worldwide and leads to
huge economic losses to swine industries. The com-
monly used and most effective strategy to control this
disease is vaccination. The antibodies elicited by vaccin-
ation are mainly targeted to the PCV2 Cap protein, the
sole and highly immunogenic structural protein of virus.
Therefore, evaluation of PCV2 antibodies after virus in-
fection or vaccination may reflect the herd infection
status or the efficacy of vaccines. Currently, the common
analytical methods developed for the qualitative and
quantitative analysis of PCV2 antibodies in serum
samples are IIF and IPMA. However, the antibodies
detected by IIF and IPMA were not PCV2-specific due
to the antigenic cross-reactivity between the Rep
proteins encoded by PCV2 and PCV1 [19]. Therefore,
development of specific and convenient methods for
Table 1 Determination of sensitivity and specificity of the




Positive 82a 3a 85a
78b 0b 78b
Negative 3a 72a 75a
7b 75b 80b
Total 85 75 160
Note:*IPMA immunoperoxidase monolayer assay, cELISA competitive enzyme-
linked immunosorbent assay
aComepetitive ELISA positive 58.4 % inhibition or greater
bComepetitive ELISA positive 70.4 % inhibition or greater
Fig. 1 Distribution of the cELISA PI values for detection of IPMA positive and negative pig sera. The horizontal bar shows the frequency of IPMA-positive
and -negative samples and the vertical bar shows the inhibition values








81–100 20 0.06–2.31 0.16–7.46
70–80 20 0.8–4.62 0.64–5.31
<60 20 2.2–14.8 5.1–14.6
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PCV2 antibody evaluation is more meaningful in PCV2
serological test.
It was previously reported that ELISA coated with the
recombinant PCV2 Cap protein or peptide could be
used for the specific detection of PCV2 antibody [8, 20].
Several indirect ELISA methods using the recombinant
Cap protein have been developed for detecting the pres-
ence of PCV2 antibody in pig sera [12–14]. However,
the indirect ELISA has some limitations including the
high level of false positives due to the complex compo-
nents of serum samples such as Rheumatoid factor and
antibodies specific for other animal serum components.
Compared with indirect ELISA, cELISA have distinct ad-
vantages. First, the secondary antibody against the tested
species is nonessential. Secondly, the nonspecific back-
ground caused by the tested sera could be lower by
using the specific anti-PCV2 MAb. A cELISA have been
previously established for the detection of PCV2 anti-
bodies [15]. In their studies, live PCV2 virions from the
cell cultures have been used as the coating antigen. The
use of live virus has the issue of biosecurity and the pro-
duction of live virus as antigen is laborious and time-
consuming. Therefore, in our study, E. coli-originated
PCV2 VLPs have been used as coating antigen with the
advantages of intact antigenicity and easier preparation.
Besides the PCV2 VLPs used as coating antigen in this
study, a PCV2-specific MAb was employed as a com-
petitor with test sera. The MAb used in this assay is not
reactive with PCV1 which exclude the inference of
PCV1 antibodies that existed in the serum samples. Both
the serum samples from experimental infected with
PCV2 and from the clinical animals were used to estab-
lish the cELISA. The sensitivity and specificity of the
cELISA was determined by detecting 160 field serums
which have been confirmed IPMA. When the cutoff
value of this cELISA was set to 58.4 % inhibition, three
IPMA positive/cELISA negative serum samples were de-
tected. These serum samples may contain antibodies to
different stain of PCV2 that were reactive by IPMA but
not with cELISA since a wide range of viral epitopes
could be recognized by the polyclonal antibodies in
IPMA. Three IPMA negative/cELISA positive samples
were also detected. This discrepancy may be explained
by the higher sensitivity of cELISA than IPMA. When
the cutoff increased to 70.4 % inhibition, the IPMA
negative/cELISA positive disappeared and the numbers
of IPMA positive/cELISA negative serums increase to
seven. Hence, the gray zone of the cELISA was set to be
in the region of 58.4 to 70.4 %, and the samples should
be retested when PI values fall into the range.
The established cELISA was next applied to do the
PCV2 serological survey by using 1297 serum samples
collected from three different provinces. The results of
the survey reveals the PCV2 antibody positive rates
ranged from 79.3 to 98.4 % which indicates the good
herd immunity after vaccination.
Conclusions
To summarize, a cELISA was successfully established in
this study to specifically detect PCV2 antibodies in ex-
clusion of PCV1 antibody interference in serum samples.
The specificity and convenience of this cELISA will be a
useful tool to evaluate the strength of post-vaccination
antibody response and monitor the efficacy of current
vaccines.
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Table 3 Prevalence of antibodies to PCV2 in pig sera collected
from Henan, Hunan, and Beijing
Areas Positive Negative Total Positive rate
Beijing city 371 6 377 98.4 %
Hunan province 348 84 432 80.6 %
Henan province 387 101 488 79.3 %
Total 1106 191 1297 85.3 %
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